3 Mai 2016 Jahr - FDA convened a joint meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee to discuss results from assessments of the extended-release and long- acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategies (REMS)
Zugefügt zum Band der Zeit:
Datum:
3 Mai 2016 Jahr
Jetzt
~ 9 years and 5 months ago